Keywords: USA, AstraZeneca, Motavizumab, Advisory panel, Respiratory syncytial virus
US FDA expresses concerns over AstraZeneca’s RSV drug motavizumab ahead of advisory panel meeting
Article | 01 June 2010
The US Food and Drug Administration last Friday posted briefing materials in advance of tomorrow’s (June 2) Antiviral Drugs Advisory ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
